Innovative Diagnostic Technology ANGLE's proprietary Parsortix system offers FDA-cleared, patent-protected circulating tumor cell harvesting technology, presenting a significant opportunity for pharma companies and clinical labs seeking advanced liquid biopsy solutions.

Strategic Industry Collaborations Recent partnerships with leading organizations like Myriad Genetics and collaborations with pharmaceutical giants such as AstraZeneca highlight potential avenues for joint research, clinical trials, and expanding the use of ANGLE's liquid biopsy technology.

Growing Market Presence Attendance and data presentation at major oncology and circulating tumor cell conferences demonstrate ANGLE’s active engagement and thought leadership, positioning it to capture increased market share in research, drug development, and diagnostics sectors.

Recent Leadership & Expansion With strategic leadership appointments and expanding clinical service offerings in the UK and US, ANGLE is poised for growth, creating opportunities for sales of diagnostic equipment, consumables, and clinical testing services worldwide.

Financial Opportunity With a revenue range of 100 to 250 million dollars and recent contract wins with major pharmaceutical companies, ANGLE presents a lucrative target for investment and sales expansion in the fast-growing liquid biopsy and oncology diagnostics market.